Unlocking acid ceramidase: a new weapon against proteasome chemoresistance in myeloma.
作者信息
Delgado-Calle Jesus
机构信息
Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, US; Department of Orthopedic Surgery; University of Arkansas for Medical Sciences, Little Rock, AR, US; Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences Little Rock, AR, US; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
出版信息
Haematologica. 2025 Jun 1;110(6):1248-1249. doi: 10.3324/haematol.2024.286925. Epub 2025 Jan 2.
Abstract
摘要
相似文献
1
Unlocking acid ceramidase: a new weapon against proteasome chemoresistance in myeloma.解锁酸性神经酰胺酶：对抗骨髓瘤蛋白酶体化学抗性的新武器。
Haematologica. 2025 Jun 1;110(6):1248-1249. doi: 10.3324/haematol.2024.286925. Epub 2025 Jan 2.
2
Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma.酸性神经酰胺酶控制蛋白酶体抑制剂耐药性，是治疗复发/难治性多发性骨髓瘤的新型治疗靶点。
Haematologica. 2025 Jun 1;110(6):1351-1367. doi: 10.3324/haematol.2024.285587. Epub 2024 Dec 5.
3
Nitric oxide induces neutral ceramidase degradation by the ubiquitin/proteasome complex in renal mesangial cell cultures.一氧化氮通过泛素/蛋白酶体复合物诱导肾系膜细胞培养物中的中性神经酰胺酶降解。
FEBS Lett. 2002 Dec 18;532(3):441-4. doi: 10.1016/s0014-5793(02)03727-4.
4
Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.Syrbactin 蛋白酶体抑制剂 TIR-199 克服硼替佐米化疗耐药性并抑制体内多发性骨髓瘤肿瘤生长。
Leuk Res. 2020 Jan;88:106271. doi: 10.1016/j.leukres.2019.106271. Epub 2019 Nov 12.
5
Conserved amino acid residues in the COOH-terminal tail are indispensable for the correct folding and localization and enzyme activity of neutral ceramidase.COOH末端尾巴中的保守氨基酸残基对于中性神经酰胺酶的正确折叠、定位及酶活性而言不可或缺。
J Biol Chem. 2004 Jul 9;279(28):29351-8. doi: 10.1074/jbc.M404012200. Epub 2004 May 3.
6
Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma.缺氧通过协调多发性骨髓瘤中 SRC-3 的去 SUMO 化和泛素化来诱导蛋白酶体抑制剂的耐药性。
Oncogene. 2022 Nov;41(45):4971-4979. doi: 10.1038/s41388-022-02494-5. Epub 2022 Oct 8.
7
PPFIBP1 activates NF-κB signaling to enhance chemoresistance of multiple myeloma.PPFIBP1激活核因子-κB信号通路以增强多发性骨髓瘤的化疗耐药性。
Transl Oncol. 2023 Nov;37:101765. doi: 10.1016/j.tranon.2023.101765. Epub 2023 Aug 22.
8
Proteasome inhibitors in the treatment of multiple myeloma.蛋白酶体抑制剂在多发性骨髓瘤治疗中的应用
Leukemia. 2009 Nov;23(11):1964-79. doi: 10.1038/leu.2009.173. Epub 2009 Sep 10.
9
Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance.去乙酰化诱导 HP1γ 核凝聚促进多发性骨髓瘤耐药性。
Nat Commun. 2023 Mar 9;14(1):1290. doi: 10.1038/s41467-023-37013-x.
10
Nitric oxide induces degradation of the neutral ceramidase in rat renal mesangial cells and is counterregulated by protein kinase C.一氧化氮可诱导大鼠肾系膜细胞中中性神经酰胺酶的降解，且蛋白激酶C可对其进行反向调节。
J Biol Chem. 2002 Nov 29;277(48):46184-90. doi: 10.1074/jbc.M204034200. Epub 2002 Sep 30.
本文引用的文献
1
Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma.酸性神经酰胺酶控制蛋白酶体抑制剂耐药性，是治疗复发/难治性多发性骨髓瘤的新型治疗靶点。
Haematologica. 2025 Jun 1;110(6):1351-1367. doi: 10.3324/haematol.2024.285587. Epub 2024 Dec 5.
2
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.多发性骨髓瘤：2020 年诊断、风险分层和治疗更新。
Am J Hematol. 2020 May;95(5):548-567. doi: 10.1002/ajh.25791.
3
The power of proteasome inhibition in multiple myeloma.蛋白酶体抑制在多发性骨髓瘤中的作用。
Expert Rev Proteomics. 2018 Dec;15(12):1033-1052. doi: 10.1080/14789450.2018.1543595. Epub 2018 Nov 14.
4
Spectrum and functional validation of PSMB5 mutations in multiple myeloma.多种骨髓瘤中 PSMB5 突变的频谱和功能验证。
Leukemia. 2019 Feb;33(2):447-456. doi: 10.1038/s41375-018-0216-8. Epub 2018 Jul 19.
5
An Platform for the Prediction of Clinical Response in Multiple Myeloma.一个用于预测多发性骨髓瘤临床反应的平台。
Cancer Res. 2017 Jun 15;77(12):3336-3351. doi: 10.1158/0008-5472.CAN-17-0502. Epub 2017 Apr 11.
6
Proteasome inhibitors in cancer therapy.蛋白酶体抑制剂在癌症治疗中的应用。
Nat Rev Clin Oncol. 2017 Jul;14(7):417-433. doi: 10.1038/nrclinonc.2016.206. Epub 2017 Jan 24.
7
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.针对多发性骨髓瘤中 prosurvival BCL2 家族蛋白的分层：MCL1 的关键作用。
Blood. 2016 Oct 6;128(14):1834-1844. doi: 10.1182/blood-2016-03-704908. Epub 2016 Jul 27.
8
Dysregulation of sphingolipid metabolism in cancer.癌症中鞘脂代谢的失调。
Cancer Biol Ther. 2011 Jan 15;11(2):138-49. doi: 10.4161/cbt.11.2.14624.
Zotero 插件